{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:40:17Z","timestamp":1775122817123,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"BANSS Foundation"},{"name":"Biedenkopf an der Lahn"},{"name":"BANSS Foundation"},{"name":"Biedenkopf an der Lahn"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1093\/annonc\/mdv617","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T04:50:11Z","timestamp":1450414211000},"page":"379-390","source":"Crossref","is-referenced-by-count":160,"title":["Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel"],"prefix":"10.1016","volume":"27","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[]},{"given":"R.E.","family":"Coleman","sequence":"additional","affiliation":[]},{"given":"C.","family":"Wilson","sequence":"additional","affiliation":[]},{"given":"T.J.","family":"Powles","sequence":"additional","affiliation":[]},{"given":"P.","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[]},{"given":"L.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"J.-J.","family":"Body","sequence":"additional","affiliation":[]},{"given":"C.","family":"Markopoulos","sequence":"additional","affiliation":[]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[]},{"given":"I.","family":"Diel","sequence":"additional","affiliation":[]},{"given":"A.","family":"Di Leo","sequence":"additional","affiliation":[]},{"given":"D.","family":"Cameron","sequence":"additional","affiliation":[]},{"given":"D.","family":"Dodwell","sequence":"additional","affiliation":[]},{"given":"I.","family":"Smith","sequence":"additional","affiliation":[]},{"given":"M.","family":"Gnant","sequence":"additional","affiliation":[]},{"given":"R.","family":"Gray","sequence":"additional","affiliation":[]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[]},{"given":"B.","family":"Thurlimann","sequence":"additional","affiliation":[]},{"given":"M.","family":"Untch","sequence":"additional","affiliation":[]},{"given":"J.","family":"Cortes","sequence":"additional","affiliation":[]},{"given":"M.","family":"Martin","sequence":"additional","affiliation":[]},{"given":"U.-S.","family":"Albert","sequence":"additional","affiliation":[]},{"given":"P.-F.","family":"Conte","sequence":"additional","affiliation":[]},{"given":"B.","family":"Ejlertsen","sequence":"additional","affiliation":[]},{"given":"J.","family":"Bergh","sequence":"additional","affiliation":[]},{"given":"M.","family":"Kaufmann","sequence":"additional","affiliation":[]},{"given":"I.","family":"Holen","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1093\/annonc\/mdv617_bb0010","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"10.1093\/annonc\/mdv617_bb0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdv617_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jsbmb.2005.04.009","article-title":"Long-term effects of aromatase inhibitors on bone","volume":"95","author":"Eastell","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1093\/annonc\/mdv617_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05349.x","article-title":"Bone turnover across the menopause transition: the role of gonadal inhibins","volume":"1192","author":"Nicks","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1093\/annonc\/mdv617_bb0035","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2013.36","article-title":"Management of cancer treatment-induced bone loss","volume":"9","author":"Coleman","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1093\/annonc\/mdv617_bb0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0055","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv617_bb0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0065","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisdottir","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0070","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdv617_bb0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0080","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv617_bb0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0090","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO.2013.54.2258","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update","volume":"32","author":"Burstein","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0095","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv617_bb0100","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0105","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv617_bb0110","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv617_bb0115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","article-title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","volume":"22","author":"Eastell","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-010-1121-7","article-title":"Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study","volume":"124","author":"Coleman","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv617_bb0125","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdv617_bb0130","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0135","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","article-title":"Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?","volume":"38","author":"Hadji","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdv617_bb0140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CBC.2010.n.030","article-title":"Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial","volume":"10","author":"Peppone","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-011-1444-z","article-title":"Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial","volume":"127","author":"Winters-Stone","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv617_bb0150","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00198-009-1083-y","article-title":"The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial","volume":"21","author":"Waltman","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdv617_bb0155","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.ejca.2010.03.037","article-title":"Meta-analysis: serum vitamin D and breast cancer risk","volume":"46","author":"Yin","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11914-010-0032-1","article-title":"The utility and limitations of FRAX: a US perspective","volume":"8","author":"Silverman","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1093\/annonc\/mdv617_bb0165","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0170","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","article-title":"Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-1201-8","article-title":"Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)","volume":"125","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv617_bb0180","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0185","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0190","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdv617_bb0195","article-title":"The role of bisphosphonates and bone health issues in Japanese breast cancer patients: efficacy of alendronate with aromatase inhibitors","volume":"24","author":"Yamada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0200","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0205","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis","volume":"18","author":"Valachis","year":"2013","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdv617_bb0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv617_bb0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","article-title":"GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdv617_bb0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/SPC.0b013e3283499c93","article-title":"Adjuvant therapy with bone-targeted agents","volume":"5","author":"Wilson","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1093\/annonc\/mdv617_bb0230","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrendo.2010.195","article-title":"Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review","volume":"7","author":"Migliorati","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1093\/annonc\/mdv617_bb0240","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv617_bb0245","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ijc.11397","article-title":"Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth","volume":"107","author":"Neudert","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0250","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","article-title":"Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo","volume":"65","author":"van der Pluijm","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0255","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0260","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0265","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-13-480","article-title":"Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial","volume":"13","author":"Banys","year":"2013","journal-title":"BMC cancer"},{"key":"10.1093\/annonc\/mdv617_bb0270","first-page":"3623","article-title":"Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study","volume":"31","author":"Hoffmann","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbo.2012.05.001","article-title":"A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts","volume":"1","author":"Brown HK","year":"2012","journal-title":"J Bone Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0280","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo","volume":"20","author":"Ottewell","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0285","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/ERC-14-0199","article-title":"Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone","volume":"21","author":"Ottewell","year":"2014","journal-title":"Endocr Relatd cancer"},{"key":"10.1093\/annonc\/mdv617_bb0290","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdv617_bb0300","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2008.10.047","article-title":"Inhibition of bone resorption and growth of breast cancer in the bone microenvironment","volume":"44","author":"Buijs","year":"2009","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdv617_bb0305","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/bcr2769","article-title":"Anti-tumour activity of bisphosphonates in preclinical models of breast cancer","volume":"12","author":"Holen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0310","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0315","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv617_bb0320","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0325","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0330","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0335","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0340","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0345","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv617_bb0350","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0355","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv617_bb0360","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv617_bb0365","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdv617_bb0370","article-title":"Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis","volume":"30","author":"Gregory","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv617_bb0375","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353\u20131361.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"10.1093\/annonc\/mdv617_bb0380","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ctrv.2012.02.007","article-title":"Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine\/paracrine microenvironment and implications for treatment with bisphosphonates","volume":"38","author":"Wilson","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdv617_bb0385","series-title":"WHO Scientific Group on Research on the Menopause in the 1990s","year":"1996"},{"issue":"suppl","key":"10.1093\/annonc\/mdv617_bb0390","article-title":"Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical Trials Group\/NRG Oncology study S0307: In: 2015 ASCO Annual Meeting","volume":"33","author":"Gralow","year":"2015"},{"key":"10.1093\/annonc\/mdv617_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju264","article-title":"Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study","volume":"106","author":"Kremer","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv617_bb0400","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","article-title":"Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis","volume":"66","author":"Haider","year":"2014","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdv617_bb0405","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","article-title":"Zoledronic acid repolarises tumour associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway","volume":"14","author":"Coscia","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1093\/annonc\/mdv617_bb0410","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo","volume":"71","author":"Benzaid","year":"2011","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935611X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341935611X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/3\/379\/16700079\/mdv617.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:51:46Z","timestamp":1624693906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341935611X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S092375341935611X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv617","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}